Oncolytics Biotech Inc. (ONCY)
NASDAQ: ONCY · Real-Time Price · USD
0.5600
+0.0038 (0.68%)
Apr 28, 2025, 4:00 PM EDT - Market closed
Company Description
Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments.
The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative advanced and metastatic breast cancer, metastatic pancreatic ductal adenocarcinoma, and anal cancer.
It has an agreement with Roche Holding AG to supply its immune checkpoint inhibitors, atezolizumab, for use in its ongoing sponsored studies.
Oncolytics Biotech Inc. was incorporated in 1998 and is headquartered in Calgary, Canada.
Oncolytics Biotech Inc.
| Country | Canada |
| Founded | 1998 |
| IPO Date | Nov 8, 1999 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 28 |
| CEO | Wayne Pisano |
Contact Details
Address: 322 11th Avenue SW, Suite 804 Calgary, AB T2R 0C5 Canada | |
| Phone | 403-670-7377 |
| Website | oncolyticsbiotech.com |
Stock Details
| Ticker Symbol | ONCY |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | CAD |
| CIK Code | 0001129928 |
| CUSIP Number | 682310875 |
| ISIN Number | CA6823108759 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Wayne F. Pisano M.B.A. | Interim Chief Executive Officer and Chairman of the Board |
| Kirk J. Look C.A., CPA | Chief Financial Officer |
| Dr. Thomas C. Heineman M.D., Ph.D. | Chief Medical Officer |
| Allison Hagerman P.Eng., P.M.P. | Vice President of Product Development |
| Amy Goodowitz Levin B.S.N., R.N. | Vice President of Clinical Operations |
| Jon Patton | Director of Investor Relations and Communication |
| Christophe Degois | Vice President of Business Development |
| John Mark Lievonen B.B.A., CM, F.C.A., FCPA, LLD, M.B.A. | Consultant |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 24, 2025 | 6-K | Report of foreign issuer |
| Apr 11, 2025 | 6-K | Report of foreign issuer |
| Apr 10, 2025 | 6-K | Report of foreign issuer |
| Apr 10, 2025 | SUPPL | Filing |
| Apr 10, 2025 | 6-K | Report of foreign issuer |
| Mar 7, 2025 | 20-F | Annual and transition report of foreign private issuers |
| Mar 7, 2025 | 6-K | Report of foreign issuer |
| Feb 25, 2025 | 6-K | Report of foreign issuer |
| Feb 19, 2025 | 6-K | Report of foreign issuer |
| Feb 18, 2025 | 6-K | Report of foreign issuer |